Triple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to Standard Treatment for Treatment-Resistant Major Depression in the Brazilian Public Health System (SUS)

NCT07052058 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Treatment-Resistant Major Depressive Disorder

Interventions

BIOLOGICAL: Tocilizumab
DRUG: Normal Saline (0.9% NaCl)

Sponsor

Hospital de Clinicas de Porto Alegre